Summary
ICRF-187 is the (+) enantiomer of the racemic mixture razoxane (ICRF-159). This compound is much more water soluble and thus could be formulated for parental use. The maximum tolerated dose in children after phase I trials was determined to be 3500 mg/M2/day × 3 days. A phase II trial of ICRF-187 was done in 21 children with solid tumors and 35 children with acute leukemia. All these patients were < 21 years of age, had recovered from previous chemotherapy, had normal liver and kidney functions, and had a life expectancy of greater than 4 weeks. ICRF-187 was administered at a dose of 3 g/M2/day for 3 days as a 4 hour infusion each day. In patients with leukemia, no objective response was seen in the bone marrow although a few patients had a decrease in peripheral blast count. There were no measurable responses seen in patients with a solid tumor. ICRF-187 was well tolerated. The major toxicity was hematopoietic depression. Significant but rare toxicities included moderate to severe nausea and vomiting, and elevation of bilirubin and transaminases. Although inactive in the current study, ICRF-187 might be more active in another schedule.
Similar content being viewed by others
References
Creaven PJ, Allen LM, Alford DA: The bioavailability in man of ICRF-159, a new antineoplastic agent. J Pharm Pharmacol 27:914–918, 1975
Repta AJ, Balterzor MJ, Bansal PC: Utilization of an enantiomer as a solution to a pharmaceutical problem: application to solubilization of 1,2-di: (4-piperazine-2,6-dione) propane. J Pharm Sci 65:238–242, 1976
Von Hoff DD, Howser D, Lewis BJ, Holcenberg J, Weiss RB, Young RC: Phase I Study of ICRF-187 using a daily for 3 days schedule. Cancer Treat Rep 65:249–252, 1981
Leisman J, Haas C, Petrik B, Hoogstraten B: Phase I evaluation of ICRF-187 (NSC 169780) in patients with advance malignancy. Proc Am Assoc Cancer Rep 21:343, 1980
Holcenberg JS, Tutsch KD, Earhart RH, Ungerleider RS, Kamen BA, Pratt CB, Gribble TJ, Glaubiger DL: Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. Cancer Treat Rev 70:703–709, 1986
Speyer JL, Green MD, Kramer E, et al.: “Prospective effect of the bispyserazinedione ICRF-187 against doxorubicininduced cardiac toxicity in women with breast cancer”. New Engl J of Med 319:745–752, 1988
Author information
Authors and Affiliations
Additional information
Address for offprints: T. Vats (POG #8462), POG Operations Office, 4949 West Pine Boulevard, Suite 2A, St. Louis, MO 63108, USA
Rights and permissions
About this article
Cite this article
Vats, T., Kamen, B. & Krischer, J.P. Phase II trial of ICRF-187 in children with solid tumors and acute leukemia. Invest New Drugs 9, 333–337 (1991). https://doi.org/10.1007/BF00183575
Issue Date:
DOI: https://doi.org/10.1007/BF00183575